Pharvaris PHVS
NASDAQ PHVS
$35.25 -0.41 (-1.15%)
As of: Sep 4, 2026 · 3:59 PM EDT

Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026)

Pharvaris' (PHVS) quarterly Cash from Financing Activities came in at -$72017.2 in Q1 2026, up 9.25% YoY from -$65917.1 in Q1 2025, and down 122.79% on a QoQ basis from $316027.3 in Q4 2025.

Analysis

Pharvaris (PHVS) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Pharvaris (PHVS) has 7 years of Cash from Financing Activities data on file, last reported at -$72017.2 in Q1 2026.

  • Quarterly Cash from Financing Activities rose 9.25% year-over-year to -$72017.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $187.8 million (up 9464.31% YoY) and the FY2025 annual result came in at $181.5 million, up 6163.71% from the prior year.
  • Cash from Financing Activities fell to -$72017.2 in Q1 2026, from $316027.3 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $69456.2 billion in Q2 2023 to a low of -$69434.8 billion in Q3 2023.
  • A 5-year average of $1.3 billion and a median of $316027.3 in 2025 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 728626264.9% in 2023, down 524286449879.51% in 2023.
  • Tracing PHVS's Cash from Financing Activities over 5 years: stood at -$163045.7 in 2022, then jumped by 172816.54% to $281.6 million in 2023, then tumbled by 99.79% to $604998.1 in 2024, then slumped by 47.76% to $316027.3 in 2025, then sank by 122.79% to -$72017.2 in 2026.
  • The last three Cash from Financing Activities figures came in at -$72017.2 (Q1 2026), $316027.3 (Q4 2025), and $187.6 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Pharvaris 2.10 Bn 1.73 Bn 85,072.10 123.06 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 123.06 Mn
Mar 31, 2026 -72,017.25
Dec 31, 2025 316,027.34
Sep 30, 2025 187.56 Mn
Jun 30, 2025 -25,921.88
Mar 31, 2025 -79,361.53
Dec 31, 2024 604,998.11
Sep 30, 2024 -1,228.32 Bn
Jun 30, 2024 1,204.46 Bn
Mar 31, 2024 863,703.23
Dec 31, 2023 281.61 Mn
Sep 30, 2023 -69,434.84 Bn
Jun 30, 2023 69,456.21 Bn
Mar 31, 2023 -60,914.29
Dec 31, 2022 -163,045.73
Sep 30, 2022 -8,896.31 Bn
Jun 30, 2022 9,414.98 Bn
Mar 31, 2022 -123,598.56
Dec 31, 2021 -708,527.56
Sep 30, 2021 -18,353.25